



Learn more about our groundbreaking tests and their potential to transform cancer screening, follow-up and monitoring at rgcc-international.com.



Telephone

+65 8084 6380

Email

info@rgcc-seasia.com



Shaping the cancer care paradigm

At RGCC, we strongly believe that personalized medicine is the future of cancer treatment. To improve the chances of successful treatment and survival, RGCC services help you to make informed decisions and formulate effective treatment plans.

Our team of scientists and medical experts conducts precise and reliable genetic tests to study cancer cells at all levels, as well as new therapeutic approaches.

RGCC REGIONAL OFFICE

RGCC Southeast Asia
2 Venture Drive #09-27 Vision Exchange
Singapore 608526
info@rgcc-seasia.com
+65 8084 6380

LABORATORY FACILITIES

RGCC International GmbH
Lindenstrasse 14
6340 Baar, Switzerland

Welmedis GmbH
Schönenbergstrasse 12
8820 Wädenswil, Switzerland

RGCC S.A.
Industrial Area of Florina
53100 Florina, Greece

RGCC Central Europe
Biozentrum, Weinbergweg 22
06120 Halle (Saale), Germany

RGCC India PVT LTD
Plot no 55, Road no 5
Aleap Industrial Area
Gajularamaram, Hyderabad, India

Member of



rgccsea.com



Know your cancer, own your journey



Oncocount test



rgccsea.com

Oncocount

Oncocount is a useful tool for physicians and patients alike. The test detects the presence of Circulating Tumor Cells (CTCs) and quantifies their concentration in the bloodstream, offering vital information. A higher number of CTCs might be associated with a greater spread of cancer.

The results from RGCC tests using CTC technology, including Oncocount, are not for diagnostic or health screening purposes.

How does Oncocount work?

- ✓ Oncocount detects the presence of CTCs and their concentration in the blood. It is used for monitoring and treatment efficacy purposes.
- ✓ Oncocount provides two crucial pieces of information: the presence of CTCs and their concentration.
- ✓ At RGCC, we employ the cutting-edge fluorescence-activated cell sorting technology to isolate CTCs. This process yields a sample of cells that are 97-99% pure and 99% viable, paving the way for further tests like molecular analysis, immunophenotyping, gene expression assays, and sensitivity assessments of various treatment agents.



Oncocount

- looks for → Circulating Tumor Cells and their concentration
- helps → Clinicians monitor cancer progression and relapse

Oncocount test

How does Oncocount help?

- ✓ Follow-up tool to monitor the cancer disease burden.
- ✓ Assessment of cancer treatment response.
- ✓ Early warning test for relapse and recurrence.

Paving the way for a healthier, cancer-free future with Oncocount!



Why choose the Oncocount test?

Oncocount uses cutting-edge technologies to identify and confirm the presence of CTCs for better assessment of cancer progression and relapse.



The test is used to detect the presence of Circulating Tumor Cells (CTCs) and their concentration in blood.



It monitors patients' status post-treatment while assessing the risk of recurrence.



Doctors turn to this test to gain critical insights into the effectiveness of cancer treatments and the potential for recurrence.



Test details



Sample type

Whole peripheral blood sample



Sample size

10-15ml of whole peripheral blood



Cancer type

Applicable for all cancer types



Analysis period

Approx. 7 days



Final results

7-10 days after sample delivery

Scan this QR code



Take your first step to get personalized cancer care.

